{"protocolSection":{"identificationModule":{"nctId":"NCT02855125","orgStudyIdInfo":{"id":"TAS-114-201"},"secondaryIdInfos":[{"id":"2016-001806-40","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Taiho Oncology, Inc.","class":"INDUSTRY"},"briefTitle":"A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1","officialTitle":"A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination With S-1 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-08-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-09-30","type":"ACTUAL"},"completionDateStruct":{"date":"2017-11-30","type":"ACTUAL"},"studyFirstSubmitDate":"2016-07-18","studyFirstSubmitQcDate":"2016-08-01","studyFirstPostDateStruct":{"date":"2016-08-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-11-24","resultsFirstSubmitQcDate":"2021-11-24","resultsFirstPostDateStruct":{"date":"2021-12-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-08-30","lastUpdatePostDateStruct":{"date":"2024-09-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Taiho Oncology, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC.\n\nThe study will be conducted internationally in 2 regions: Asian \\[Japan\\] and Western \\[Europe and US\\]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1 ratio.","detailedDescription":"Randomization will take place once the consented patient has completed all the necessary baseline procedures and is deemed eligible for study entry. Treatment assignment will be done centrally using a dynamic allocation method (biased coin) via an interactive voice/web response system (IXRS) stratified by:\n\n* Geographical region (Region 1: Asian \\[Japan\\]; Region 2: Western \\[Europe and US\\])\n* Histological subtypes (nonsquamous cell carcinoma \\[including mixed\\] and squamous cell carcinoma)"},"conditionsModule":{"conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"keywords":["NSCLC","phase 2 study","TAS-114","S-1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":128,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"TAS-114 + S-1","type":"ACTIVE_COMPARATOR","description":"Participants received 400 milligrams (mg) of TAS-114 tablets orally twice daily (BID) along with 30 milligrams per meter square (mg/m\\^2) of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks).","interventionNames":["Drug: TAS-114","Drug: S-1"]},{"label":"S-1 (Monotherapy)","type":"ACTIVE_COMPARATOR","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks).","interventionNames":["Drug: S-1"]}],"interventions":[{"type":"DRUG","name":"TAS-114","description":"TAS-114 was a modulator of 5-fluorouracil (5-FU).","armGroupLabels":["TAS-114 + S-1"]},{"type":"DRUG","name":"S-1","description":"S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.","armGroupLabels":["S-1 (Monotherapy)","TAS-114 + S-1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free Survival (PFS) Based on Central Independent Review","description":"Progression-free survival was defined as the time (in months) from the day of randomization to the start of radiologic disease progression or death (any cause), whichever occurred first. Response assessments were made based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). As per RECIST 1.1 criteria, progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). (Note: the appearance of one or more new lesions was also considered progressions). Participants who did not have disease progression or died were censored at the last known time that the participant was progression free.","timeFrame":"From date of randomization or until date of disease progression or death whichever occurred first (approximately up to 13 months)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as the time from the first dose of the study treatment to death from any cause. Participants who were alive at the end of study were censored at the last date the participant was known to be alive. OS was estimated from Kaplan-Meier method.","timeFrame":"From date of randomization until death (approximately up to 15 months)"},{"measure":"Overall Response Rate (ORR) Based on Central Independent Review","description":"ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and non-target lesions and normalization of tumor marker level. Any pathological and non-pathological lymph nodes must have reduction in short axis to less than (\\<) 10 mm. PR was defined as at least a 30 percent (%) decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters.","timeFrame":"From date of first dose of study drug to the date of first documentation of progression or death (approximately up to 13 months)"},{"measure":"Disease Control Rate (DCR) Based on Central Independent Review","description":"DCR was defined as the percentage of participants with objective evidence CR, PR, or stable disease (SD). Based on the central review of tumor assessments per RECIST, version 1.1. CR was defined as disappearance of all target lesions. Reduction in any pathological lymph nodes in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameters during study.","timeFrame":"From date of first dose of study drug to the date of first documentation of progression or death (approximately up to 13 months)"},{"measure":"Duration of Response (DR) Based on Central Independent Review","description":"DR was derived for participants with objective evidence of PR or CR. DR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause. Participants who were alive and progression-free as of the analysis cut-off date were censored at their last evaluable tumor response assessment before initiation of any new anticancer treatment.","timeFrame":"From date of first response to the date of first documentation of progression or death (approximately up to 13 months)"},{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","description":"An adverse event (AE) was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened during the TEAE period which was defined as the period from the time of first dose of study treatment until 30 days after last dose of study treatment. AEs included both serious and non- serious adverse events.","timeFrame":"From first dose of study drug up to 30 days after the last dose of study drug (approximately up to 13 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥ 18 years old (≥ 20 years old in Japan);\n2. Histologically diagnosed or cytologically proven advanced or metastatic NSCLC patients, either Stage IIIB/Stage IV disease (according to Version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or recurrent disease following radiation therapy or surgical resection;\n3. Patients who had received at least 2 prior therapies for advanced or metastatic disease condition, including platinum doublet and pemetrexed, docetaxel, or immunotherapy, and were refractory to or unable to tolerate their last prior therapy\n4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009);\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;\n6. Predicted life expectancy of at least 3 months;\n7. Able to take medications orally;\n8. Adequate organ function\n9. Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.\n10. Willing and able to comply with required scheduled visits and study procedures.\n\nExclusion Criteria:\n\n1. Treatment with any of the following within the specified time frame prior to the study drug administration:\n\n   * Major surgery within prior 4 weeks and minor surgery within 7 days;\n   * Radiotherapy for extended field within prior 4 weeks or limited field within prior 2 weeks;\n   * Any anticancer therapy or investigational agent within prior 3 weeks.\n2. A serious illness or medical condition\n3. Concomitant treatment with the following drugs that may interact with S-1:\n\n   Sorivudine, brivudine, uracil, eniluracil, folinate/folinic acid, Cimetidine, dipyridamole, and nitroimidazoles, including metronidazole and misonidazoleMethotrexate, Clozapine,Allopurinol,Phenytoin,Flucytosine, a fluorinated pyrimidine antifungal agent,Coumarin-derivative anticoagulant\n4. Known hypersensitivity to S-1 or its metabolites (eg, 5-FU);\n5. Previous use of TAS-114, S-1, and 5-FU drugs;\n6. A pregnant or lactating female or possibly pregnant women, or men or women wishing to have children during the study period;\n7. A judgment of the investigator that the patient is inappropriate for study participation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Taiho Central","affiliation":"Taiho Oncology, Inc. USA","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Loma Linda","state":"California","country":"United States","geoPoint":{"lat":34.04835,"lon":-117.26115}},{"city":"Gainesville","state":"Florida","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"city":"Cleveland","state":"Ohio","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"city":"Portland","state":"Oregon","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"city":"Dallas","state":"Texas","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"city":"Seattle","state":"Washington","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"city":"Caen","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"city":"Lille","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"city":"Marseille","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Pierre-Bénite","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"city":"Villejuif","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"city":"Catania","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"city":"Palermo","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"city":"Ravenna","country":"Italy","geoPoint":{"lat":44.41344,"lon":12.20121}},{"city":"Kashiwa","state":"Chiba","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"city":"Sayama","state":"Osaka","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"city":"Adachi","state":"Saitama","zip":"362-0806","country":"Japan"},{"city":"Chuo-Ku","state":"Tokyo","country":"Japan"},{"city":"Koto-Ku","state":"Tokyo","zip":"135-8550","country":"Japan"},{"city":"Sunto-Gun","state":"Tokyo","country":"Japan"},{"city":"Wakayama","zip":"641-8509","country":"Japan","geoPoint":{"lat":34.23333,"lon":135.16667}},{"city":"Katowice","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"city":"Lodz","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"city":"Lublin","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"city":"Badalona","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}}]},"referencesModule":{"references":[{"pmid":"32246224","type":"DERIVED","citation":"Yamamoto N, Hayashi H, Planchard D, Moran T, Gregorc V, Dowell J, Sakai H, Yoh K, Nishio M, Cortot AB, Benhadji KA, Soni N, Huang J, Makris L, Cedres S. A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. Invest New Drugs. 2020 Oct;38(5):1588-1597. doi: 10.1007/s10637-020-00930-5. Epub 2020 Apr 3."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 128 participants were randomized.1 participant in S-1 (Monotherapy) arm was randomized but not treated.","recruitmentDetails":"The study was conducted at 26 centers in 5 countries.","groups":[{"id":"FG000","title":"TAS-114 + S-1","description":"Participants received 400 milligrams (mg) of TAS-114 tablets orally twice daily (BID) along with 30 milligrams per meter square (mg/m\\^2) of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"FG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"64"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"63"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"64"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Clinical Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Radiologic Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"39"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"On Treatment","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Randomized but not treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Baseline population included all participants randomized in the study, regardless of whether they actually received any study treatment (TAS-114 or S-1) or not.","groups":[{"id":"BG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"BG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.8","spread":"7.77"},{"groupId":"BG001","value":"62.6","spread":"10.22"},{"groupId":"BG002","value":"63.2","spread":"9.06"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"39"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"89"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"92"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"23"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"60"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"42"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"26"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) Based on Central Independent Review","description":"Progression-free survival was defined as the time (in months) from the day of randomization to the start of radiologic disease progression or death (any cause), whichever occurred first. Response assessments were made based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). As per RECIST 1.1 criteria, progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). (Note: the appearance of one or more new lesions was also considered progressions). Participants who did not have disease progression or died were censored at the last known time that the participant was progression free.","populationDescription":"Intent-to-Treat (ITT) population included all participants randomized in the study, regardless of whether they actually received any study treatment (TAS-114 or S-1) or not.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From date of randomization or until date of disease progression or death whichever occurred first (approximately up to 13 months)","groups":[{"id":"OG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"OG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","lowerLimit":"2.69","upperLimit":"5.16"},{"groupId":"OG001","value":"4.17","lowerLimit":"2.60","upperLimit":"6.60"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2744","statisticalMethod":"Log Rank","statisticalComment":"1-sided stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.88","estimateComment":"Based on stratified Cox regression model ."}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from the first dose of the study treatment to death from any cause. Participants who were alive at the end of study were censored at the last date the participant was known to be alive. OS was estimated from Kaplan-Meier method.","populationDescription":"ITT population.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From date of randomization until death (approximately up to 15 months)","groups":[{"id":"OG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"OG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"64"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.92","lowerLimit":"6.28","upperLimit":"10.78"},{"groupId":"OG001","value":"9.82","lowerLimit":"7.66","upperLimit":"13.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1431","statisticalMethod":"Log Rank","statisticalComment":"1-sided stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"1.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.80","ciUpperLimit":"2.14","estimateComment":"Based on stratified Cox regression model."}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) Based on Central Independent Review","description":"ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and non-target lesions and normalization of tumor marker level. Any pathological and non-pathological lymph nodes must have reduction in short axis to less than (\\<) 10 mm. PR was defined as at least a 30 percent (%) decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters.","populationDescription":"Tumor response (TR) population included all participants randomized in the study, regardless of whether they actually received any study treatment (TAS-114 or S-1) or not; with measurable disease (at least one target lesion) at baseline and with at least one tumor evaluation (participants who had disease progression or had a cancer related death prior to their 1st tumor evaluation were also considered evaluable).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of first dose of study drug to the date of first documentation of progression or death (approximately up to 13 months)","groups":[{"id":"OG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"OG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"58"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","lowerLimit":"10.6","upperLimit":"31.8"},{"groupId":"OG001","value":"10.3","lowerLimit":"3.9","upperLimit":"21.2"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR) Based on Central Independent Review","description":"DCR was defined as the percentage of participants with objective evidence CR, PR, or stable disease (SD). Based on the central review of tumor assessments per RECIST, version 1.1. CR was defined as disappearance of all target lesions. Reduction in any pathological lymph nodes in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameters during study.","populationDescription":"TR population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From date of first dose of study drug to the date of first documentation of progression or death (approximately up to 13 months)","groups":[{"id":"OG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"OG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"58"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","lowerLimit":"68.2","upperLimit":"89.4"},{"groupId":"OG001","value":"75.9","lowerLimit":"62.8","upperLimit":"86.1"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DR) Based on Central Independent Review","description":"DR was derived for participants with objective evidence of PR or CR. DR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause. Participants who were alive and progression-free as of the analysis cut-off date were censored at their last evaluable tumor response assessment before initiation of any new anticancer treatment.","populationDescription":"TR population.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From date of first response to the date of first documentation of progression or death (approximately up to 13 months)","groups":[{"id":"OG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"OG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","lowerLimit":"2.37","upperLimit":"4.86"},{"groupId":"OG001","value":"NA","lowerLimit":"2.79","upperLimit":"NA","comment":"Median and upper limit of 95% Confidence interval were not estimable because of censoring in 5 of the 6 participants."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","description":"An adverse event (AE) was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened during the TEAE period which was defined as the period from the time of first dose of study treatment until 30 days after last dose of study treatment. AEs included both serious and non- serious adverse events.","populationDescription":"Analysis was performed on As-Treated (AT) population which included all participants who received at least 1 dose of TAS-114 or S-1.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study drug up to 30 days after the last dose of study drug (approximately up to 13 months)","groups":[{"id":"OG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks)."},{"id":"OG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"63"}]}],"classes":[{"title":"Participants with TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"}]}]},{"title":"Participants with TESAEs","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"19"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first dose of study drug up to 30 days after the last dose of study drug (approximately up to 13 months)","description":"Analysis was performed on As-Treated (AT) population which included all participants who received at least 1 dose of TAS-114 or S-1.","eventGroups":[{"id":"EG000","title":"TAS-114 + S-1","description":"Participants received 400 mg of TAS-114 tablets orally BID along with 30 mg/m\\^2 of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks).","deathsNumAffected":36,"deathsNumAtRisk":64,"seriousNumAffected":30,"seriousNumAtRisk":64,"otherNumAffected":64,"otherNumAtRisk":64},{"id":"EG001","title":"S-1 (Monotherapy)","description":"Participants received 30 mg/m\\^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks).","deathsNumAffected":29,"deathsNumAtRisk":63,"seriousNumAffected":19,"seriousNumAtRisk":63,"otherNumAffected":61,"otherNumAtRisk":63}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Tracheo-oesophageal fistula","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Hypopituitarism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Pituitary-dependent Cushing's syndrome","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Mechanical ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":63}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Pneumonia influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Metabolic alkalosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":63}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Respiratory acidosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Stevens-Johnson syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":111,"numAffected":42,"numAtRisk":64},{"groupId":"EG001","numEvents":26,"numAffected":17,"numAtRisk":63}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":63}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":63}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":63}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":63}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":64},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":63}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":19,"numAtRisk":64},{"groupId":"EG001","numEvents":24,"numAffected":18,"numAtRisk":63}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":20,"numAtRisk":64},{"groupId":"EG001","numEvents":62,"numAffected":23,"numAtRisk":63}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":10,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":63}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":12,"numAtRisk":64},{"groupId":"EG001","numEvents":18,"numAffected":13,"numAtRisk":63}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":19,"numAtRisk":64},{"groupId":"EG001","numEvents":22,"numAffected":14,"numAtRisk":63}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":6,"numAtRisk":64},{"groupId":"EG001","numEvents":18,"numAffected":11,"numAtRisk":63}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":10,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":63}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":63}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":63}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":63}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":14,"numAtRisk":64},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":63}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":63}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":63}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":63}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":12,"numAffected":5,"numAtRisk":63}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":6,"numAtRisk":64},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":63}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":8,"numAtRisk":64},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":63}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":10,"numAtRisk":64},{"groupId":"EG001","numEvents":10,"numAffected":5,"numAtRisk":63}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":29,"numAtRisk":64},{"groupId":"EG001","numEvents":44,"numAffected":27,"numAtRisk":63}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":63}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":63}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":63}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":63}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":63}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":63}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":64},{"groupId":"EG001","numEvents":15,"numAffected":7,"numAtRisk":63}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":64},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":63}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":63}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":63}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":63}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":64},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":63}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":15,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":63}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":18,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":63}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":18,"numAtRisk":64},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":63}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":63}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Taiho Central","organization":"Taiho Oncology, Inc.","email":"medicalinformation@taihooncology.com","phone":"+1 844-878-2446"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-09-27","uploadDate":"2021-11-22T05:23","filename":"Prot_000.pdf","size":3454035},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-11-29","uploadDate":"2021-11-22T05:25","filename":"SAP_001.pdf","size":2848313}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000657359","term":"TAS-114"},{"id":"C079198","term":"S 1 (combination)"}]}},"hasResults":true}